Stay updated on Ociperlimab, Tislelizumab, Chemotherapy in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab, Tislelizumab, Chemotherapy in Metastatic NSCLC Clinical Trial page.

Latest updates to the Ociperlimab, Tislelizumab, Chemotherapy in Metastatic NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.3%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check17 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference6%
- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check60 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check67 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
Stay in the know with updates to Ociperlimab, Tislelizumab, Chemotherapy in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab, Tislelizumab, Chemotherapy in Metastatic NSCLC Clinical Trial page.